Saxonov Serge 4

What Happened
Serge Saxonov, CEO of 10x Genomics (TXG), sold a total of 15,000 shares in open-market transactions: 10,000 shares on March 23, 2026 at a weighted-average price of $19.13 (proceeds ~$191,297) and 5,000 shares on March 24, 2026 at a weighted-average price of $19.52 (proceeds ~$97,612). Total proceeds from these sales were roughly $288,909. These were sales (not purchases); sales are often routine and do not by themselves indicate a change in the insider’s view of the company.

Key Details

• Transaction dates and prices:
  • Mar 23, 2026 — 10,000 shares, Wtd. avg price $19.13 (reported range $18.78–$19.41 per footnote).
  • Mar 24, 2026 — 5,000 shares, Wtd. avg price $19.52 (reported range $19.49–$19.59 per footnote).
• Total shares sold: 15,000; total proceeds ≈ $288,909.
• Shares owned after transaction: Not specified in this Form 4 filing.
• Notable footnotes:
  • Trades were effected under a Rule 10b5-1 trading plan adopted Nov 29, 2025 (F1) — prearranged plan.
  • Filing discloses multiple trust relationships and prior transfers (e.g., transfers to Sirius Trust and Y/S Pot Trust on Mar 3, 2026; several 2018 irrevocable trusts hold 250,000 shares each of which the reporting person is trustee) (F3, F9, F10, F11).
  • Weighted-average prices reflect multiple trades; the filer offers to provide per-trade breakdown to the SEC or issuer upon request (F2, F4).
• Timeliness: Report filed Mar 25, 2026 for transactions on Mar 23–24 — appears timely (no late filing flag).

Context

• These sales were executed under a 10b5-1 plan, which typically means trades were pre-scheduled and may not reflect contemporaneous insider views.
• For retail investors: purchases by insiders tend to be more informative than routine, pre-planned sales; treat this filing as a disclosure of liquidity by the insider rather than a directional signal.